EPHB1 Antibody

What is EPHB1 and why is it important in research?

EPHB1 is a receptor tyrosine kinase belonging to the ephrin receptor family with significant roles in diverse biological processes including nervous system development, angiogenesis, and neural synapsis formation and maturation. It is a type 1 membrane-spanning protein composed of multiple domains: immunoglobulin, fibronectin type III, and cysteine-rich subdomains in the ectodomain, followed by a single uninterrupted cytoplasmic tyrosine kinase domain and a carboxy-terminal sterile alpha motif (SAM) domain . EPHB1 binds ephrin-B class ligands, which are also transmembrane proteins capable of transmitting signals, creating a bidirectional signaling system. This receptor is predominantly expressed in developing neural structures in embryos and in vascular epithelium of kidney and other tissues . The importance of EPHB1 in research stems from its involvement in cell attachment regulation and cell-cell assembly upon binding to ephrin B1, as well as its implication in neuronal and vascular cell targeting .

What are the key considerations when selecting an EPHB1 antibody?

When selecting an EPHB1 antibody, researchers should consider several critical factors to ensure experimental success. First, evaluate the antibody's validated applications—whether it has been tested for Western blot (WB), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), or other techniques relevant to your research . For instance, antibodies like MA5-15385 are validated for indirect ELISA, IHC, and WB applications with human samples .

Second, consider the epitope recognition—the specific region of EPHB1 that the antibody recognizes. Some antibodies target specific domains or phosphorylation sites, which may be crucial depending on your research question. The MA5-15385 antibody, for example, was generated using a purified recombinant fragment of EPHB1 (amino acids 19-133) expressed in E. coli .

Third, verify species reactivity to ensure compatibility with your experimental system. Lastly, check for potential cross-reactivity with other EPH family members, as these proteins share significant sequence homology. Performing validation experiments with positive and negative controls is essential before proceeding with critical experiments.

How can EPHB1 expression be accurately quantified in tissue samples?

Accurate quantification of EPHB1 expression in tissue samples requires a multi-faceted approach. For protein-level quantification, Western blot analysis using validated antibodies like those targeting the specific domains of EPHB1 provides semi-quantitative measurements. When performing Western blots, researchers should lyse 1-2 × 10^6 cells in appropriate buffer (such as RIPA or laemmli sample buffer), separate proteins by SDS-PAGE, and use primary antibodies specific to EPHB1 with appropriate controls .

For more sensitive detection in clinical samples, immunohistochemistry can be employed using antibodies such as clone 88512 (R&D systems) with appropriate visualization methods . Flow cytometry offers another quantitative approach, particularly useful for analyzing EPHB1 expression in heterogeneous cell populations or for distinguishing between membrane and intracellular expression.

For mRNA-level quantification, quantitative RT-PCR provides a sensitive method to assess EPHB1 transcript levels, though correlation with protein expression should be verified. In clinical contexts, combining these approaches provides the most comprehensive assessment of EPHB1 expression patterns and can help distinguish between normal and pathological expression levels.

What is the recommended protocol for detecting EPHB1 using Western blot?

The recommended protocol for detecting EPHB1 using Western blot involves several critical steps to ensure specific and sensitive detection. First, prepare cell lysates from 1-2 × 10^6 cells using an appropriate lysis buffer such as RIPA buffer with protease inhibitors . For protein quantification, use the Pierce BCA Protein assay or equivalent method .

For protein separation, load 15-20 μg of protein on a 4-12% Bis-Tris gradient gel and run at approximately 180V for 1 hour . Transfer proteins to a nitrocellulose membrane using standard transfer methods (20V for 8 minutes using iBlot transfer stacks or equivalent systems) .

For EPHB1 detection, block the membrane with 3-5% non-fat milk or BSA in TBST followed by incubation with primary anti-EPHB1 antibody at appropriate dilution (typically 1:1,000 to 1:2,000) . For FLAG-tagged EPHB1 constructs, mouse monoclonal anti-FLAG antibody (such as Sigma-Aldrich #F3165) can be used . Include proper loading controls such as β-Actin (1:10,000 dilution) . Use appropriate HRP-conjugated secondary antibodies (typically 1:5,000 to 1:10,000 dilution) and visualize using chemiluminescence detection systems .

Important considerations include: 1) EPHB1 has a predicted molecular weight of approximately 110 kDa ; 2) fresh lysates generally produce better results than frozen samples; 3) complete transfer of high molecular weight proteins may require extended transfer times; and 4) quantification should be performed using image analysis software with appropriate normalization to loading controls .

How should EPHB1 ligand stimulation experiments be designed and executed?

EPHB1 ligand stimulation experiments require careful design to effectively activate and study receptor signaling. The recommended protocol involves several key steps:

• Cell preparation: Plate 5 × 10^5 cells at 50% confluency in appropriate culture vessels and incubate overnight .

• Starvation: Prior to stimulation, cells should be serum-starved in media containing minimal serum (0.1% BSA) for 24 hours at 37°C to reduce baseline receptor activation .

• Ligand clustering: Pre-cluster ephrin-B1-Fc ligands by mixing with anti-Fc antibodies in a 2:1 molar ratio and incubating at room temperature for 2 hours . This clustering mimics the membrane-bound presentation of ephrin ligands and is essential for proper receptor activation.

• Stimulation: Treat starved cells with pre-clustered ephrin-B1-Fc at appropriate concentrations (typically 1-5 μg/ml). Include control treatments using pre-clustered Fc fragments without ephrin-B1 .

• Time course: Collect samples at multiple time points (typically 5, 15, 30, 60 minutes) to capture the dynamics of receptor activation and downstream signaling events.

• Analysis: Assess receptor activation by Western blot using phospho-specific antibodies, particularly against tyrosine phosphorylation sites. Additionally, analyze downstream signaling cascades by examining the phosphorylation status of key proteins such as ATR, Chk1, p21, and CDK1 (Tyr15) .

This experimental design allows for robust analysis of EPHB1 forward signaling and its effects on cellular processes such as cell cycle progression, apoptosis, and migration.

What are the optimal conditions for EPHB1 immunoprecipitation experiments?

For successful EPHB1 immunoprecipitation (IP) experiments, researchers should implement the following optimized protocol:

• Lysate preparation: Harvest 5-10 × 10^6 cells and lyse in a non-denaturing IP buffer (typically containing 1% NP-40 or Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, and protease/phosphatase inhibitors) for 30 minutes on ice with occasional vortexing.

• Pre-clearing: Pre-clear lysates with protein A/G beads (20-30 μl) for 1 hour at 4°C to reduce non-specific binding.

• Antibody binding: Incubate pre-cleared lysates with 2-5 μg of EPHB1-specific antibody overnight at 4°C with gentle rotation. For tagged EPHB1 constructs, anti-tag antibodies (such as anti-FLAG) can be used .

• Immunoprecipitation: Add 30-50 μl of protein A/G beads and incubate for 2-4 hours at 4°C with gentle rotation.

• Washing: Wash the beads 4-5 times with cold IP buffer, collecting the beads by gentle centrifugation (1,000 × g for 1 minute) between washes.

• Elution: Elute bound proteins by adding SDS sample buffer and heating at 95°C for 5 minutes.

• Analysis: Analyze immunoprecipitated proteins by Western blot, probing for EPHB1 and potential interacting partners or phosphorylation status.

To detect specific phosphorylation events, use phospho-specific antibodies in Western blot analysis after IP. Alternatively, perform IP with phospho-tyrosine antibodies followed by EPHB1 detection. When studying EPHB1 interactions with ephrin ligands or other proteins, crosslinking prior to lysis can help preserve transient interactions.

How do EPHB1 mutations affect receptor function in cancer contexts?

EPHB1 mutations in cancer contexts can significantly alter receptor function through multiple mechanisms. Recent structure-based bioinformatic analysis of pan-cancer mutations identified several recurring EPHB1 mutations with distinct functional consequences . These mutations cluster in functionally important domains including the ligand-binding domain, fibronectin domain, and kinase domain.

Mutations in the ligand-binding domain (such as C61Y, R90C, and R170W) and the fibronectin domain (R351L) typically result in reduced to strongly compromised cell compartmentalization, a critical function for maintaining tissue organization . These mutations also exhibit reduced ligand-induced receptor phosphorylation, suggesting impaired forward signaling capabilities. The kinase domain mutation D762N similarly compromises compartmentalization function .

In contrast, certain kinase domain mutations (R743W and G821R) actually enhance cell compartmentalization functions, though this enhancement is not directly linked to altered receptor phosphorylation levels . This suggests alternative mechanisms affecting receptor function beyond canonical kinase activity.

Phosphoproteomic analysis of cells expressing EPHB1 mutants with reduced compartmentalization has identified alterations in the PI3K pathway, particularly affecting PIK3C2B phosphorylation . This provides a potential mechanistic link between EPHB1 mutations and altered cellular signaling networks that could contribute to cancer progression.

These findings underscore the complex and domain-specific effects of EPHB1 mutations in cancer, with implications for understanding the role of this receptor in tumorigenesis and potential therapeutic targeting strategies.

What role does EPHB1 play in the DNA damage response pathway?

EPHB1 plays a crucial and previously underappreciated role in the DNA damage response (DDR) pathway, particularly in the context of acute myelogenous leukemia (AML). Research has revealed that EPHB1 activation through ephrin-B1 ligand binding triggers a signaling cascade that modulates key components of the DDR system .

Stimulation of EPHB1-expressing AML cells with ephrin-B1 leads to increased phosphorylation of ATR (Ataxia Telangiectasia and Rad3-related protein) and Checkpoint kinase 1 (Chk1), central regulators of the DDR pathway . This activation is accompanied by increased expression of the cell cycle inhibitor p21 and enhanced inhibitory phosphorylation of CDK1 at Tyrosine 15, collectively enforcing a G2-M cell cycle arrest .

Phospho-proteome analysis of ephrin-B1-stimulated cells has further revealed increased phosphorylation of additional cell cycle regulators including p27, p38, and p53 . The integration of these signals culminates in programmed cell death, as evidenced by downregulation of the anti-apoptotic protein Bcl-2 and upregulation of the pro-apoptotic protein Bax .

Importantly, reintroduction of EPHB1 expression in AML cells with methylated EPHB1 promoters enhances this same cascade of ATR, Chk1, p21, and CDK1 Tyr15 phosphorylation, reinforcing the critical role of EPHB1 in this pathway . These findings identify EPHB1 as a tumor suppressor in AML through its function in the DDR system, with potential implications for therapeutic interventions targeting this pathway.

How can EPHB1 receptor shedding be accurately measured?

EPHB1 receptor shedding, a process mediated by metalloproteases like ADAM17, can be accurately measured using a combination of complementary techniques:

• ADAM17 ELISA method: This approach quantifies the involvement of ADAM17 in EPHB1 cleavage. The protocol involves treating cells (e.g., 1 × 10^6 THP-1 cells) with ephrin-B1 or leaving them untreated for 24 hours . Cells are then collected in cell lysis buffer supplemented with 1 mmol/L phenyl-methylsulfonylfluoride and analyzed for ADAM17 protein expression using commercially available ELISA kits (e.g., human ADAM17/TACE duoset) . This method has successfully demonstrated that ephrin-B1 stimulation increases ADAM17 protein expression in THP-1 cells, suggesting induced EPHB1 cleavage .

• Western blot detection of cleaved fragments: Researchers can detect soluble extracellular domains and membrane-retained C-terminal fragments of EPHB1 through Western blot analysis of conditioned media and cell lysates, respectively. This requires antibodies targeting different domains of EPHB1 to distinguish full-length versus cleaved forms.

• Flow cytometry for surface receptor quantification: This technique measures changes in cell surface EPHB1 levels following stimulation with ephrin ligands or metalloprotease activators. Decreased surface staining over time can indicate receptor internalization or shedding, which can be distinguished by simultaneous analysis of soluble receptor fragments.

• Fluorescence-based assays: Cells expressing EPHB1 tagged with fluorescent proteins at N- and C-termini allow real-time monitoring of receptor shedding through differential localization of fluorescent signals.

When designing experiments to measure EPHB1 shedding, researchers should include metalloprotease inhibitors (such as TIMP-3 or GM6001) as controls to confirm the specific involvement of these enzymes in the observed receptor cleavage.

How is EPHB1 expression altered in different cancer types?

Conversely, in solid tumors, the pattern of EPHB1 expression and its functional implications can vary significantly. In colorectal cancer, EPHB1 mutations rather than complete loss of expression have been observed, particularly in metastatic cases . These mutations alter receptor function in ways that may contribute to cancer progression, such as compromised cell compartmentalization which could facilitate tumor cell invasion .

The table below summarizes the patterns of EPHB1 alterations across different cancer types:

These diverse patterns highlight the importance of cancer-specific analysis of EPHB1 expression and function when considering its potential as a biomarker or therapeutic target.

What methods are recommended for analyzing EPHB1 promoter methylation status?

Analysis of EPHB1 promoter methylation status is particularly important given the evidence that hypermethylation contributes to EPHB1 suppression in cancers like AML . Several complementary methods are recommended for comprehensive methylation analysis:

• Bisulfite Sequencing: This gold-standard approach involves treating DNA with bisulfite, which converts unmethylated cytosines to uracils while leaving methylated cytosines unchanged. The treated DNA is then amplified using EPHB1 promoter-specific primers, followed by sequencing to quantify methylation at individual CpG sites. This provides single-nucleotide resolution of methylation patterns across the entire promoter region.

• Methylation-Specific PCR (MSP): This technique uses primer sets designed to specifically amplify either methylated or unmethylated versions of the bisulfite-converted EPHB1 promoter. MSP offers a rapid assessment of methylation status but with lower resolution than sequencing methods.

• Quantitative Methylation-Specific PCR (qMSP): This method combines MSP with real-time PCR to quantify the relative levels of methylated and unmethylated EPHB1 promoter sequences, providing a more precise measurement of methylation density.

• Pyrosequencing: This technique offers quantitative assessment of DNA methylation at multiple CpG sites with high accuracy and reproducibility. It is particularly useful for analyzing specific regions within the EPHB1 promoter that may be most relevant to transcriptional regulation.

• Methylation Arrays: Genome-wide methylation arrays include probes for the EPHB1 promoter region and can be used to simultaneously assess methylation patterns across multiple genes, allowing for comparative analysis across different regulatory regions.

When analyzing EPHB1 promoter methylation, it is critical to correlate methylation patterns with expression data (mRNA and protein levels) and functional outcomes to establish the biological significance of the observed methylation changes. In clinical samples, comparison with matched normal tissues provides important context for interpreting methylation alterations.

How can EPHB1 antibodies be utilized in patient stratification for clinical trials?

EPHB1 antibodies can be powerful tools for patient stratification in clinical trials, particularly in cancers where EPHB1 expression or mutations have prognostic significance. Implementation strategies include:

• Immunohistochemistry (IHC) Scoring Systems: Develop standardized IHC protocols using validated EPHB1 antibodies (such as clone 88512 from R&D systems) to quantify EPHB1 expression in tumor samples. A semi-quantitative scoring system based on staining intensity and percentage of positive cells can categorize patients into distinct expression groups (negative, low, moderate, high). In AML, for example, lower EPHB1 expression has been associated with poorer outcomes , making this a potential stratification marker.

• Mutation-Specific Detection: For trials targeting specific EPHB1 mutations, develop antibodies that specifically recognize common mutant forms (such as C61Y, R90C, or R170W) . This approach requires validation of antibody specificity against wild-type and various mutant EPHB1 proteins.

• Phosphorylation Status Assessment: Since EPHB1 signaling activity depends on its phosphorylation, antibodies specifically recognizing phosphorylated forms can identify patients with active EPHB1 signaling versus those with inactive receptors despite protein expression.

• Multiplex Immunofluorescence Panels: Combine EPHB1 antibodies with markers of related pathways (such as ATR, Chk1, or PI3K pathway components) to create comprehensive panels that better characterize tumor signaling networks and potentially identify synergistic therapeutic opportunities.

• Circulating Tumor Cell (CTC) Analysis: Apply EPHB1 antibodies in CTC isolation and characterization to monitor changes in EPHB1 expression or phosphorylation during treatment, potentially identifying early markers of response or resistance.

For clinical implementation, it is essential to establish clear cutoff values through correlative studies linking EPHB1 expression or mutation status with clinical outcomes. Additionally, standardization across laboratories through reference standards and proficiency testing will ensure consistent patient classification across multiple trial sites.

What are common pitfalls when using EPHB1 antibodies and how can they be addressed?

When working with EPHB1 antibodies, researchers frequently encounter several technical challenges that can compromise experimental results. Understanding these pitfalls and implementing appropriate solutions is critical for generating reliable data.

One common issue is non-specific binding, particularly in Western blot applications. This can result from the high sequence homology between EPHB1 and other EPH family members. To address this, researchers should perform careful antibody validation using positive controls (cells with confirmed EPHB1 expression) and negative controls (EPHB1 knockout cells or cells with EPHB1 silencing) . Additionally, optimizing antibody dilution and blocking conditions can significantly reduce background and increase specificity.

Another challenge is detecting low abundance EPHB1 protein, especially in clinical samples or cells with physiological expression levels. Enhancing detection sensitivity through signal amplification systems or using concentration techniques like immunoprecipitation before Western blotting can help overcome this limitation . For tissues with heterogeneous EPHB1 expression, techniques like laser capture microdissection prior to analysis may prevent dilution of signal from positive cells.

Variability in antibody performance between lots can also introduce inconsistency in experimental results. Researchers should maintain reference samples with known EPHB1 expression levels to calibrate new antibody lots and ensure comparable sensitivity and specificity.

For phosphorylation-specific detection, rapid dephosphorylation during sample preparation can lead to false negative results. This can be mitigated by including phosphatase inhibitors in all buffers and maintaining samples at cold temperatures throughout processing .

Finally, epitope masking due to protein-protein interactions or conformational changes can prevent antibody binding. Using multiple antibodies targeting different EPHB1 epitopes and employing various sample preparation methods (native vs. denaturing conditions) can help overcome this limitation.

How should researchers optimize EPHB1 immunofluorescence staining protocols?

Optimizing EPHB1 immunofluorescence staining protocols requires attention to several critical parameters to achieve specific and sensitive detection. The following comprehensive optimization strategy is recommended:

• Fixation method selection: Compare multiple fixation approaches (4% paraformaldehyde, methanol, or acetone) to determine which best preserves EPHB1 epitopes while maintaining cellular morphology. For membrane receptor detection, paraformaldehyde fixation (10-15 minutes at room temperature) often provides optimal results.

• Permeabilization optimization: If detecting intracellular domains or internalized receptors, test different permeabilization agents (0.1-0.5% Triton X-100, 0.1-0.5% Saponin, or 100% cold methanol) and durations (5-15 minutes) to achieve balanced permeabilization without epitope destruction.

• Blocking buffer formulation: Develop an effective blocking solution typically containing 5-10% normal serum (from the same species as the secondary antibody) in PBS with 0.1-0.3% Triton X-100. For tissues with high background, adding 1-2% BSA and 0.1-0.3% glycine can further reduce non-specific binding.

• Antibody titration: Perform systematic titration experiments with primary antibodies (starting range: 1:50 to 1:500) to identify the optimal concentration that maximizes specific signal while minimizing background. For EPHB1 detection, validated antibodies like clone 5F10A4 or clone 88512 have been successfully used in immunofluorescence applications .

• Incubation conditions: Compare overnight incubation at 4°C versus 1-3 hours at room temperature to determine optimal primary antibody incubation conditions. For secondary antibodies, 1-2 hours at room temperature is typically sufficient.

• Signal amplification: For low-abundance EPHB1 detection, implement signal amplification systems such as tyramide signal amplification or quantum dots as alternative fluorophores.

• Controls implementation: Always include positive controls (cells/tissues with confirmed EPHB1 expression), negative controls (EPHB1-negative samples), and technical controls (primary antibody omission) to validate staining specificity.

For co-localization studies with other proteins, sequential staining protocols may be necessary to prevent antibody cross-reactivity. Additionally, when analyzing EPHB1 clustering upon ligand stimulation, pre-fixation with mild crosslinkers can help preserve these transient structures for subsequent microscopic analysis.

What approaches can resolve contradictory results when studying EPHB1 functions?

Resolving contradictory results in EPHB1 functional studies requires systematic investigation of potential variables that might influence experimental outcomes. The following comprehensive approach can help reconcile discrepancies:

What emerging technologies are advancing EPHB1 antibody applications in research?

Several cutting-edge technologies are significantly enhancing EPHB1 antibody applications in research, opening new avenues for understanding this receptor's biology and pathological roles. Single-cell proteomics techniques now allow researchers to analyze EPHB1 expression and phosphorylation status at the individual cell level, revealing heterogeneity within seemingly uniform populations. This approach is particularly valuable for studying EPHB1 in complex tissues where expression may vary between adjacent cells.

Proximity labeling methods using EPHB1 antibodies conjugated to enzymes like BioID or APEX2 enable identification of the receptor's protein interaction networks in living cells. When EPHB1 is activated, these enzymes tag nearby proteins, creating a snapshot of the receptor's interactome during signaling events. This approach has potential to uncover novel EPHB1-interacting partners that may influence its function in different cellular contexts.

Advanced imaging technologies including super-resolution microscopy techniques (STORM, PALM, STED) coupled with EPHB1-specific antibodies now allow visualization of receptor clustering and compartmentalization at nanoscale resolution. These approaches can directly visualize how mutations affect EPHB1 spatial organization, complementing functional compartmentalization assays .

Mass cytometry (CyTOF) combined with EPHB1 antibodies enables simultaneous detection of dozens of other proteins, providing comprehensive signaling network analysis. This approach can reveal how EPHB1 activation influences multiple downstream pathways simultaneously, helping to resolve context-dependent signaling outcomes.

Lastly, spatially resolved transcriptomics combined with EPHB1 protein detection through antibody staining creates multi-omic profiles that link receptor activation to transcriptional responses with spatial context preserved. These integrated approaches will likely resolve many outstanding questions about EPHB1's diverse and sometimes contradictory functions in development and disease.

How can EPHB1 antibodies contribute to therapeutic development?

EPHB1 antibodies hold significant potential for therapeutic development through multiple mechanisms and applications. They can serve as targeting agents for antibody-drug conjugates (ADCs) in cancers where EPHB1 is overexpressed, delivering cytotoxic payloads specifically to cancer cells while sparing normal tissues. For developing effective ADCs, antibodies must be carefully selected for high specificity to EPHB1 and efficient internalization upon binding.

In contexts where EPHB1 activation is therapeutically desirable, such as in AML where it demonstrates tumor suppressor functions , agonistic antibodies could mimic ephrin binding to trigger receptor activation. Such antibodies would need to induce receptor clustering similar to natural ligands, potentially activating the DNA damage response pathway that leads to cell cycle arrest and apoptosis in leukemic cells .

Conversely, for situations where EPHB1 signaling promotes disease progression, antagonistic antibodies that block ligand binding or receptor dimerization could inhibit unwanted EPHB1 activation. The development of domain-specific antibodies is particularly relevant given the different functions associated with mutations in distinct EPHB1 domains .

Beyond direct therapeutic applications, EPHB1 antibodies are essential for patient stratification in clinical trials through immunohistochemical analysis of tumor samples. As demonstrated in AML, EPHB1 expression status correlates with prognosis , suggesting its utility as a biomarker. Developing standardized EPHB1 immunohistochemistry protocols with validated antibodies could help identify patients most likely to benefit from specific treatments.

Additionally, EPHB1 antibodies can facilitate pharmacodynamic monitoring in early-phase clinical trials of drugs targeting this receptor or its downstream pathways. By measuring changes in EPHB1 expression or phosphorylation following treatment, researchers can confirm target engagement and establish optimal dosing schedules.

What are the current challenges and future opportunities in EPHB1 research?

The field of EPHB1 research faces several significant challenges while simultaneously presenting exciting opportunities for future investigation. One major challenge is reconciling the context-dependent roles of EPHB1 across different tissues and disease states. While EPHB1 functions as a tumor suppressor in AML through activation of the DNA damage response pathway , its mutations in colorectal cancer alter receptor compartmentalization in ways that may promote metastasis . Developing comprehensive models that account for these tissue-specific functions remains difficult but essential for therapeutic targeting.

Technical challenges persist in studying EPHB1 protein-protein interactions under physiological conditions. The transient nature of these interactions, particularly with ephrin ligands and downstream signaling molecules, makes them difficult to capture with conventional biochemical approaches. Advanced methodologies including proximity labeling, live-cell imaging of fluorescently tagged proteins, and EPHB1 interactome mapping will be crucial for overcoming these limitations.

The dynamic regulation of EPHB1 through mechanisms including receptor shedding by ADAM17 , endocytosis, and recycling introduces complexity that current experimental approaches struggle to fully capture. Developing tools to monitor these processes in real-time will provide important insights into EPHB1 biology.

Future opportunities include exploring the therapeutic potential of targeting EPHB1 in cancers where it serves as a tumor suppressor. Strategies to restore EPHB1 expression in cancers with epigenetic silencing, such as through DNA methyltransferase inhibitors, warrant investigation . For cancers harboring specific EPHB1 mutations, the development of mutation-specific therapeutic approaches based on functional consequences (e.g., altered compartmentalization or kinase activity) represents an exciting frontier .